Impact of donor type on outcomes of allogeneic transplant

Human leukocyte antigen (HLA)-matched sibling donors (MSD) are the ideal donors for allogeneic hematopoietic stem cell transplantation (allo-HSCT), however, MSDs are only available in 30% of cases.¹ Using other donor types increases the risk of graft-versus-host disease (GvHD) and non-relapse mortality (NRM), though may promote an allo-immune effect against the tumor, thereby reducing the risk of relapse. Overall, diagnosis and disease status at time of transplant remain the main drivers of transplant outcome. ¹

The development and increased clinical usage of reduced-intensity conditioning (RIC) regimens and GvHD prophylactic agents have made transplantation an option for more patients. Roni Shouval, Joshua A Fein, and colleagues, hypothesized that the effect on overall survival (OS) and NRM due to the genetic disparity between donor and recipient may have diminished over time. Therefore, they conducted an analysis of adult patients who underwent allo-HSCT for a hematological malignancy between 2001 and 2015, using the European Society for Blood and Marrow Transplantation (EBMT) registry. The stem cell source was either peripheral blood (PB), bone marrow (BM) or umbilical cord blood (UC). They aimed to determine the impact of the donor source on OS, NRM, relapse incidence, progression-free survival (PFS), acute GvHD (aGvHD), chronic GvHD (cGvHD) and GvHD-free relapse-free survival (GRFS).

Study design and patient characteristics

• Retrospective, multicenter study of 106,188 patients receiving allo-HSCT
• Median follow-up: 4.1 years (interquartile range: 1.7–7.7)
• Patients were arranged into three epochs based on when they received their transplant:
  • 1: 2001–2005 (n= 23,249)
  • 2: 2006–2010 (n= 35,348)
  • 3: 2011–2015 (n= 47,591)
• Donor types:
  • MSD; matched at HLA-A, HLA-B, and HLA-DRB1
  • Matched unrelated (MUD); matched at HLA-A, HLA-B, HLA-C, and HLA-DRB1
  • Mismatched unrelated (MMUD); unrelated donor with ≥ one mismatch in: HLA-A, HLA-B, HLA-C, HLA-DRB1
  • Haploidentical (HD); sibling or relative with ≥ two mismatches at HLA-A, HLA-B, and HLA-DRB1
  • Cord blood (CD); unrelated
• Most patients received allo-HSCT for acute leukemia (epoch 1 vs 2 vs 3): 50.2% vs 57.8% vs 57.8% and most were low risk (epoch 1 vs 2 vs 3): 52.9% vs 51.8% vs 53.2%
• The proportion of patients receiving transplant from unrelated donors increased, with mismatched sibling donor transplants decreasing (Table 1)

Table 1. Transplant stem cell source and donor type, by epoch

Epoch

1 (%)

2 (%)

3 (%)

Donor type

MSD

59.5

44.1

34.4

MUD

3.3

24.6

32.7

MMUD

2.3

8.8

8.6

Unrelated, HLA unknown

32.5

15.6

15.2

HD

1.2

2.6

6.3

CD

1.3

4.3

2.8

Cell source

PB

73.7

81.5

84.8

BM

24.4

13.3

12.0

PB and BM

0.6

0.8

0.5

UC

1.3

4.3

2.8

Results

The investigators compared the outcomes between epochs one and two, and two and three. Some of these were statistically significant (p< 0.05), as indicated in Table 2.

Three-year OS:

• Increased across all epochs
• Increased in MSD transplant
• Increased between epochs 2 and 3 for MUD, HD, and CD transplants

Three-year NRM:

• Decreased in epoch 3, especially in HD, and somewhat in MSD, MUD and MMUD transplant
• For CD transplant, NRM was similar across the epochs, but was reduced between epochs 2 and 3
• Proportion of patients experiencing relapse over time did not differ
• Main causes of NRM in epoch 3:
  • Infection in HD (33.7%) and CD (31.1%)
  • GvHD in MSD (36.3%), MUD (31.7%) and MMUD (32.0%)
• Graft rejection in epoch 3 as cause of NRM (HD vs MMUD vs CD vs MUD vs MSD): 9.5% vs 6.4% vs 5.7% vs 5.4% vs 3.5%

Table 2. Outcomes by epoch and donor type

 

 

Estimate (%)

FDR-adjusted Cox p value

 

n

Epoch 1
(2001-05)

Epoch 2
(2006-10)

Epoch 3
(2011-15)

Epoch 1 vs 2

Epoch 2 vs 3

Three-year OS

106,188

46.3

48.7

50.5

<0.0001

<0.0001

MSD

45,489

51.2

54.0

54.6

0.0005

0.0083

MUD

24,939

46.0

49.1

51.6

0.25

<0.0001

MMUD

7,722

41.4

37.4

41.3

0.34

0.0033

HD

4,174

23.0

34.5

44.2

0.46

0.0033

CD

3,130

37.1

36.3

43.7

0.46

0.0086

Three-year NRM

105,332

27.2

25.3

23.5

<0.0001

<0.0001

MSD

45,094

22.6

19.8

18.1

<0.0001

<0.0001

MUD

24,825

24.4

26.3

24.8

0.081

<0.0001

MMUD

7,685

31.3

36.6

33.4

0.82

0.028

HD

4,142

59.3

39.8

27.3

0.12

0.0033

CD

3,105

38.4

34.1

33.0

0.16

0.15

Three-year relapse incidence

105,332

34.0

33.6

34.1

0.045

0.46

MSD

45,094

34.5

35.6

36.8

0.47

0.44

MUD

24,825

37.1

31.8

31.0

0.45

0.36

MMUD

7,685

35.8

30.6

32.4

0.069

0.33

HD

4,142

21.8

31.6

33.2

0.051

0.87

CD

3,105

30.8

34.7

28.7

0.85

0.0001

Three-year PFS

105,332

38.8

41.0

42.4

<0.0001

<0.0001

MSD

45,094

42.9

44.6

45.0

0.054

0.10

MUD

24,825

38.4

41.9

44.2

0.22

<0.0001

MMUD

7,685

32.9

32.8

34.3

0.24

0.023

HD

4,142

19.0

28.6

39.5

0.82

0.055

CD

3,105

30.7

31.2

38.2

0.44

0.0001

GvHD

• Full analysis of outcomes for GvHD by donor type and epoch are shown in Table 3
• Severe aGvHD (grade III­-IV):
  • Decreased moderately between MSD transplant recipients between epochs 1 and 2
    • Epoch 1 vs 2: 9.7% (95% CI, 9.2–10.3) vs 8.4% (95% CI, 7.9–8.8), p= 0.0002
  • Increased amongst CD recipients between epochs 2 and 3
    • Epoch 2 vs 3: 11.1% (95% CI, 9.4–12.8) vs 14.8% (95% CI, 12.7–16.8), p= 0.046
• Extensive cGvHD
  • Modest reduction led to increase in GRFS
• GRFS: improved with all donor types in epoch three

Table 3. GvHD outcomes by epoch and donor type

 

 

Estimate (%)

FDR-adjusted Cox p value

 

n

Epoch 1 (2001-05)

Epoch 2 (2006-10)

Epoch 3 (2011-15)

Epoch 1 vs 2

Epoch 2 vs 3

One-year grade ≥ II aGvHD

99,625

27.1

25.0

25.4

<0.01

0.84

MSD

42,525

26.2

22.0

22.3

<0.01

0.84

MUD

23,741

33.0

26.5

27.8

0.51

0.56

MMUD

7,368

34.1

30.9

29.4

<0.01

0.19

HD

3,966

16.4

22.0

25.2

0.21

0.19

CD

2,940

24.6

29.0

33.5

0.33

0.17

One-year grade ≥ III aGvHD

99,625

10.4

9.4

9.7

<0.01

0.68

MSD

42,525

9.7

8.4

8.6

<0.01

0.78

MUD

23,741

13.2

9.1

10.1

0.25

0.82

MMUD

7,368

15.8

13.0

12.0

0.01

0.07

HD

3,966

4.7

8.1

8.9

0.25

0.25

CD

2,940

8.8

11.1

14.8

0.43

0.05

Three-year extensive cGvHD

93,864

14.1

13.9

11.9

0.28

<0.01

MSD

40,160

15.7

16.2

14.2

0.57

<0.01

MUD

22,021

19.5

14.0

12.3

0.72

0.07

MMUD

7,035

12.1

12.5

11.4

<0.01

<0.01

HD

3,856

7.4

7.8

7.2

0.97

0.07

CD

2,912

4.2

5.8

7.7

0.44

0.47

Three-year GRFS

86,408

25.8

27.8

30.7

<0.01

<0.01

MSD

36,492

27.9

28.9

31.1

0.02

<0.01

MUD

20,522

23.3

29.3

32.4

0.46

<0.01

MMUD

6,558

24.3

22.7

24.3

<0.01

<0.01

HD

3,660

14.8

20.6

33.2

0.82

0.02

CD

2,659

21.3

23.6

27.4

0.45

0.02

Risk stratification model

The authors developed a risk stratification scheme, categorizing patients in low-, intermediate-, and high-risk based on their disease, time from diagnosis, disease status, and cytogenetics. Using MSD as a reference category, the authors also compared outcomes by donor type within the risk categories. Epoch 3 served as the validation cohort, with results of multivariate analysis as below:

Overall mortality and NRM

• Intermediate- and high-risk: associated with increased hazard ratio (HR) for overall mortality
  • Intermediate-risk: HR= 1.24, (95% CI, 1.20–1.28)
  • High-risk: HR= 2.29, (95% CI, 2.21–2.38)
• MSD transplants had lowest overall mortality risk over all risk categories
• Hazard for all-cause mortality in the low- and intermediate-risk groups was higher with MUD:
  • Low-risk: HR= 1.22, (95% CI, 1.16–1.28), p< 0.0001
  • Intermediate-risk: HR= 1.12, (95% CI, 1.05–1.20), p= 0.0004
• NRM was higher with MUD in all categories but particularly in the low-risk group (HR= 1.45, [95% CI, 1.34–1.56], p< 0.0001)

Risk of Relapse

• Decreased risk of relapse was observed with low- and intermediate-risk MUD:
  • Low-risk: HR= 0.89, (95% CI, 0.84–0.95), p= 0.0003
  • Intermediate-risk: HR= 0.86, (95% CI, 0.80–0.92), p< 0.0001
• HD transplant showed a lower risk of relapse compared to MSD in the low- and intermediate-risk groups indicating a graft-versus-tumor effect. However, this benefit was not seen in the high-risk group possibly due to immune surveillance escape
  • Low-risk: HR= 0.83 (95% CI, 0.73–0.96), p= 0.011
  • Intermediate-risk: HR= 0.85, (95% CI, 0.74–0.99), p= 0.033
  • High-risk: HR= 1.14, (95% CI, 1.0–1.3), p= 0.053
• MUD transplant: across all risk categories, patients were less prone to relapse
  • Indicates graft-versus-tumor effect

Conclusions

OS has improved over time, across all donor types which appears to be driven by a decrease in NRM. The authors hypothesized that this is due to the use of RIC regimens and better supportive care. The biggest reduction in NRM was in patients receiving HD transplant, likely due to the use of post-transplant cyclophosphamide (PTCy) over anti-thymocyte globulin (ATG). PTCy appears to be an effective way to overcome HLA disparities.

In epoch 3 (transplant between 2011 and 2015), 24–33% of patients achieved an optimal outcome, were alive and relapse free without extensive GvHD at three-years post-transplant. Patients categorized as low- or intermediate-risk, who received an MSD transplant, had the lowest hazard for mortality. In high-risk disease though, similar hazards for mortality were observed between recipients of MUD and MSD transplant.  

The incidence of cGvHD declined across the epochs, which the authors hypothesized is due to the use of ATG. ATG was used in 75% of HD transplants in epoch 2, whilst PTCy was used in 76% in epoch 3 indicating both are valid strategies to prevent GvHD.

Despite this, GRFS is only achieved by ~30% of patients. Current strategies to increase GRFS include;

• High-resolution HLA-matching
• Biomarker-driven approaches
• Modification of the microbiome
• Targeting immunosuppression

The authors concluded that the traditional hierarchy of donors (MSD, MUD and then other donors) remains true. The findings of this analysis may help guide further studies, and lead to the development of an algorithm to aid the selection of the most appropriate donor.